Physician profile
Alan J Wayne
NPI 1477531283
$8,520.44
in general payments reported to CMS, 2019-2025
38 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $1,108 · 2021: $1,762 · 2022: $1,406 · 2023: $1,133 · 2024: $1,385 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,964.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,554.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,410.00 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,016.24 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $830.69 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $680.09 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $437.02 | 2021-2025 | Caplyta |
| Lundbeck LLC | $294.01 | 2021-2024 | Rexulti |
| Sk Life Science, INC. | $283.92 | 2020-2024 | |
| Pfizer INC. | $252.99 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.51 | 2019-2023 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $152.25 | 2021 | |
| Astellas Pharma US INC | $126.78 | 2020-2024 | Veozah |
| Amgen INC. | $115.62 | 2019 | |
| Sumitomo Pharma America, INC. | $106.35 | 2024 | Aptiom, Gemtesa |
| Otsuka America Pharmaceutical, INC. | $91.69 | 2022-2025 | Rexulti, Abilify Maintena |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Wayne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.